Q3 2016 EPS Estimates for Mazor Robotics Ltd. Boosted by First Analysis (MZOR)
Mazor Robotics Ltd. (NASDAQ:MZOR) – First Analysis raised their Q3 2016 earnings per share (EPS) estimates for Mazor Robotics in a research note issued on Thursday. First Analysis analyst G. Chodaczek now expects that the brokerage will earn ($0.16) per share for the quarter, up from their previous estimate of ($0.20). First Analysis also issued estimates for Mazor Robotics’ Q4 2016 earnings at ($0.06) EPS, FY2016 earnings at ($0.61) EPS, Q1 2017 earnings at ($0.12) EPS, Q2 2017 earnings at ($0.07) EPS and FY2017 earnings at ($0.25) EPS.
A number of other research firms have also issued reports on MZOR. Barclays PLC upped their target price on shares of Mazor Robotics from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, October 11th. B. Riley assumed coverage on shares of Mazor Robotics in a report on Tuesday, October 11th. They set a “neutral” rating and a $25.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a report on Wednesday, October 12th. Finally, Zacks Investment Research lowered shares of Mazor Robotics from a “hold” rating to a “sell” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. Mazor Robotics currently has an average rating of “Hold” and an average price target of $26.25.
Shares of Mazor Robotics (NASDAQ:MZOR) opened at 22.89 on Monday. The company’s market cap is $496.09 million. Mazor Robotics has a 12-month low of $8.31 and a 12-month high of $26.55. The stock has a 50 day moving average of $23.40 and a 200 day moving average of $18.53.
Mazor Robotics (NASDAQ:MZOR) last released its earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. The firm earned $8.30 million during the quarter, compared to analyst estimates of $8.51 million. Mazor Robotics had a negative net margin of 60.75% and a negative return on equity of 42.30%. The business’s revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.05) EPS.
Large investors have recently made changes to their positions in the stock. Cookson Peirce & Co. Inc. purchased a new stake in shares of Mazor Robotics during the second quarter worth about $192,000. Trellus Management Company LLC raised its stake in shares of Mazor Robotics by 11.6% in the second quarter. Trellus Management Company LLC now owns 23,982 shares of the company’s stock worth $431,000 after buying an additional 2,500 shares in the last quarter. Menta Capital LLC raised its stake in shares of Mazor Robotics by 81.9% in the first quarter. Menta Capital LLC now owns 37,482 shares of the company’s stock worth $466,000 after buying an additional 16,879 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in shares of Mazor Robotics during the second quarter worth about $1,079,000. Finally, Iguana Healthcare Management LLC raised its stake in shares of Mazor Robotics by 384.6% in the first quarter. Iguana Healthcare Management LLC now owns 121,151 shares of the company’s stock worth $1,507,000 after buying an additional 96,151 shares in the last quarter. 18.72% of the stock is owned by hedge funds and other institutional investors.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.